Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

NCT01088724 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Post-transplant Lymphoproliferative Disease (PTLD)
Non Burkitt

Interventions

DRUG: fludarabine, cyclophosphamide, doxorubicin, rituximab

Sponsor

A.O. Ospedale Papa Giovanni XXIII